# evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease

Article · Jeffrey L. Cummings, Alireza Atri, Howard Feldman, Oskar Hansson, Mary Sano, Filip Krag Knop, Peter Johannsen, Teresa León, Philip Scheltens

- Archive id: doi:10.1186/s13195-024-01666-7
- Published: 2025-01-08
- Venue: Alzheimer s Research & Therapy
- DOI: https://doi.org/10.1186/s13195-024-01666-7
- PMID: 39780249
- Citations: 165
- Source URL: https://doi.org/10.1186/s13195-024-01666-7
- PDF: https://alzres.biomedcentral.com/counter/pdf/10.1186/s13195-024-01666-7
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.